<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7429942\results\search\testTrace\results.xml">
  <result pre="(NMD) patients. The risk of a severe course of SARS-CoV-2" exact="infection" post="is increased in all but the mildest forms of"/>
  <result pre="oropharyngeal weakness and risk of worsening with fever, fasting or" exact="infection" post="Isolation requirements may have an impact on treatment regimens"/>
  <result pre="fasting or infection Isolation requirements may have an impact on" exact="treatment" post="regimens administered in hospital settings, such as nusinersen, glucosidase"/>
  <result pre="immunoglobulin, and rituximab infusions. In addition, specific drugs for SARS-CoV2" exact="infection" post="under investigation impair neuromuscular function significantly; chloroquine and azithromycin"/>
  <result pre="lives of more than 400,000 individuals worldwide (https://coronavirus.jhu.edu/map.html). Symptomatic SARS-CoV-2" exact="infection" post="causes a wide spectrum of symptoms (referred to as"/>
  <result pre="manifestations in severe disease courses (Fig.Â 1). In parallel, SARS-CoV-2" exact="infection" post="poses a greater risk for old, oncologic, and immunosuppressed"/>
  <result pre="different organs and systems possibly involved in coronavirus disease-19 (COVID-19)" exact="infection" post="and it summarizes some pathophysiological and clinical-related features. The"/>
  <result pre="neuromuscular disorders will probably encounter. The NMD patient without SARS-CoV-2" exact="infection" post="Risk assessment and stratification Risk assessment and stratification are"/>
  <result pre="and families and their physicians to prevent and manage SARS-CoV-2" exact="infection" post="in this category [6â€&quot;9]. Overall, these documents recognize that"/>
  <result pre="Primary cardiac involvement Risk of deterioration with fever, fasting or" exact="infection" post="Risk of rhabdomyolysis with fever, fasting or infection Concomitant"/>
  <result pre="fasting or infection Risk of rhabdomyolysis with fever, fasting or" exact="infection" post="Concomitant diabetes, obesity, neoplastic diseases, severe cerebrovascular diseases or"/>
  <result pre="secondary to fever and infections. In addition, patients receiving steroid" exact="treatment" post="might undergo an adrenal crisis during fever or infection"/>
  <result pre="steroid treatment might undergo an adrenal crisis during fever or" exact="infection" post="if steroid dosage is not adjusted [11]. Patients with"/>
  <result pre="by the authorities), the shortage of PPE and the increased" exact="infection" post="risk for patients imposed consistent changes in the management"/>
  <result pre="suspended unless urgent cases required further evaluations (such as new" exact="diagnosis" post="of amyotrophic lateral sclerosis, myasthenia, myositis, or immune-mediated neuropathies)."/>
  <result pre="to quickly identify NMD patients who suffered from severe SARS-CoV-2" exact="infection" post="in other regions/states of the country and promptly manage"/>
  <result pre="recent example of a neurologic examination at-distance comprises a suspected" exact="diagnosis" post="of SARS-CoV-2 infection in a young patient with Charcotâ€&quot;Marieâ€&quot;Tooth"/>
  <result pre="a neurologic examination at-distance comprises a suspected diagnosis of SARS-CoV-2" exact="infection" post="in a young patient with Charcotâ€&quot;Marieâ€&quot;Tooth polyneuropathy undergoing post-surgical"/>
  <result pre="used in NMD patients that may increase the risk of" exact="infection" post="or a more severe disease course. As a general"/>
  <result pre="which immunosuppressive drugs can contribute to severe forms of SARS-CoV-2" exact="infection" post="is still unclear. Depending on the regional pandemic burden,"/>
  <result pre="for myasthenia gravis (MG)) [40] may increase the risk of" exact="infection" post="or a severe disease course. Immunomodulant therapies currently used"/>
  <result pre="some cytokine inhibition strategies are currently being tested for the" exact="treatment" post="of COVID-19, such as Tocilizumab and Eculizumab, but their"/>
  <result pre="and extending refill periods [42]. The NMD patient with SARS-CoV-2" exact="infection" post="SARS-CoV-2 infection in NMD patients Clinical syndromes associated with"/>
  <result pre="refill periods [42]. The NMD patient with SARS-CoV-2 infection SARS-CoV-2" exact="infection" post="in NMD patients Clinical syndromes associated with SARS-CoV-2 infection"/>
  <result pre="SARS-CoV-2 infection in NMD patients Clinical syndromes associated with SARS-CoV-2" exact="infection" post="have been classified by the World Health Organization (WHO)"/>
  <result pre="care [38]. Patients receiving corticosteroids might require an increase in" exact="treatment" post="doses due to the risk of infection-triggered hyposurrenalism [38]."/>
  <result pre="to the risk of infection-triggered hyposurrenalism [38]. However, decisions regarding" exact="treatment" post="de-escalation should be individualized according to the severity of"/>
  <result pre="We suggest preparing an Emergency card stating specific respiratory and" exact="treatment" post="needs of the single patient, including settings for ventilatory"/>
  <result pre="sought and promptly provided whenever doubts arise regarding the proper" exact="treatment" post="of NMD patients. Even in the case of critically"/>
  <result pre="[46]. Three of them developed severe respiratory insufficiency following the" exact="infection" post="and required intubation or high-flow oxygen, whereas two had"/>
  <result pre="Indications of therapy discontinuation in immunosuppressed MG patients during the" exact="infection" post="are uncertain [38]. Although this patient population lacks a"/>
  <result pre="disease after recovery [46]. In some MG patients, SARS-CoV-2 pulmonary" exact="infection" post="may directly induce an MG crisis [46, 47]. Oxygen"/>
  <result pre="WHO recommends that all patients with SARS-CoV-2 severe acute respiratory" exact="infection" post="(SARI) are started immediately with supplemental oxygen therapy at"/>
  <result pre="improvement [7]. ETI and mechanical ventilation remain the mainstay of" exact="treatment" post="for unstable patients with ARDS and acute respiratory insufficiency."/>
  <result pre="been approved (Table 3). Table 3 Experimental treatments for SARS-CoV-2" exact="infection" post="Drug Results so far Potential NMD-relevant side effects Chloroquine"/>
  <result pre="75]. Lopinavir/Ritonavir (LPV/RTV) is an antiviral drug used for the" exact="treatment" post="of HIV. A randomized Chinese trial found no efficacy"/>
  <result pre="(www.clinicaltrials.gov). Remdesivir is a novel nucleotide analogue developed for the" exact="treatment" post="of Ebola and Marburg viruses. Remdesivir was shown to"/>
  <result pre="ARDS [79]. It is now being studied as an adjunctive" exact="treatment" post="for patients with COVID-19, with apparently positive results, but"/>
  <result pre="with proinflammatory and prothrombotic properties. The use of Eculizumab for" exact="treatment" post="of severe COVID-19 is currently being investigated in a"/>
  <result pre="84]. The most dangerous complication that may arise during short-term" exact="treatment" post="with such agents is QTc prolongation and arrhythmias [62,"/>
  <result pre="assessment before use in myopathic patients, and, in case of" exact="treatment" post="with these agents, regular monitoring of serum CK levels."/>
  <result pre="was favourable. Overall, the literature on NMD patients with SARS-CoV-2" exact="infection" post="is limited in number and general considerations are difficult."/>
  <result pre="7.World Health Organization (2020) Clinical management of severe acute respiratory" exact="infection" post="when novel coronavirus (nCoV) infection is suspected: interim guidance."/>
  <result pre="management of severe acute respiratory infection when novel coronavirus (nCoV)" exact="infection" post="is suspected: interim guidance. https://apps-who-int.pros.lib.unimi.it:2050/iris/handle/10665/330854. Accessed 26 Apr 2020"/>
  <result pre="services across the care continuumBMJ Global Health20205e002670 36.PradaVBelloneESchenoneAGrandisMThe suspected SARS-Cov-2" exact="infection" post="in a Charcot-Marie-Tooth patient undergoing postsurgical rehabilitation: the value"/>
  <result pre="summaryNeurology20168741942527358333 40.GableKLGuptillJTAntagonism of the neonatal Fc receptor as an emerging" exact="treatment" post="for myasthenia gravisFront Immunol202010.3389/fimmu.2019.0305231998320 41.QinCZhouLHuZZhangSYangSTaoYet al.Dysregulation of immune response"/>
  <result pre="Mailhe M, et al. (2020) Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
  <result pre="of ebola virus disease therapeuticsN Engl J Med20193812293230331774950 68.DiurnoFNumisFGPortaGCirilloFMaddalunoSRagozzinoAet al.Eculizumab" exact="treatment" post="in patients with COVID-19: preliminary results from real life"/>
  <result pre="agentsPNAS198178360536096115382 70.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J2005211015631631 71.KeyaertsEVijgenLMaesPNeytsJRanstMVIn vitro inhibition of severe acute"/>
  <result pre="and Health Commission of Guangdong Province for chloroquine in the" exact="treatment" post="of novel coronavirus pneumoniaExpert Consens Chloroquine Phosphate Treat Novel"/>
  <result pre="vitroCell Res20203026927132020029 74.GaoJTianZYangXBreakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBioScience Trends202014727332074550 75.Molina"/>
  <result pre="Qiu L, Liu X, Liu D, Li J (2020) Tocilizumab" exact="treatment" post="in COVID-19: a single center experience. J Med Virol"/>
  <result pre="(2020) Guidance on minimizing risk of drug-induced ventricular arrhythmia during" exact="treatment" post="of COVID-19: a statement from the canadian heart rhythm"/>
 </snippets>
</snippetsTree>
